| Value | ₹100.0 Cr |
|---|
BSE filing, NSE: SENORES. Summary written from the filing by ALFA Finder's alert engine.
Senores Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,114.30
- Market cap
- ₹5,132 Cr
- Revenue (annual)
- ₹632.6 Cr
- Net profit (annual)
- ₹115.4 Cr
- P/E (TTM)
- 38.5×Sector 48.7×
- Promoter holding
- 45.82%+0.00% QoQ
- FII holding
- 6.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Senores Pharmaceuticals Ltd
All →Senores Pharmaceuticals Earnings Call Transcript: Key Takeaways
Senores delivered record quarterly revenue and EBITDA, driven by US portfolio expansion and regulated market growth.
- Call
- Guides 40% growth
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals reported no deviation in utilising the Rs 95 Crore raised via a preferential warrant issue for the quarter ended September 30, 2026. Audit Committee reviewed the statement and the Board took it on record.
- Value
- ₹95.00 Cr
Senores Pharmaceuticals Capacity Expansion: ₹20 Cr Investment
Senores Pharmaceuticals' subsidiary Apnar Pharma Private Limited plans a 0.7 Bn unit capacity addition by March 2027. The investment is Rs.20.00 Crore, funded by internal accruals and IPO proceeds.
- Value
- ₹20.00 Cr
- Execution
- By end of March 2027
- production capacity
- 0.7 Bn units
Senores Pharmaceuticals Capacity Expansion: ₹18 Cr Investment
Senores Pharmaceuticals plans to add 0.8 Bn units of capacity to its existing 1.2 Bn unit plant by March 2027. The investment is Rs.18.00 Crore, funded by internal accruals and IPO proceeds.
- Value
- ₹18.00 Cr
- Execution
- By end of March 2027
- production capacity
- 0.8 Bn units
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals appointed Talati and Talati LLP as Statutory Auditor for a 60-month term, effective 29 October 2026. The appointment was approved at the board meeting held the same day.
- Execution
- 60 months
Senores Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹192.3 Cr (+24.9%), EBITDA ₹57.7 Cr (+38.3%, 30.0% margin), PAT ₹36.6 Cr. H1 revenue +30%, EBITDA +58.2%.
Other fund raise announcements
All →Gujarat Inject (Kerala) Fund Raise of ₹3 Cr
Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.
- Value
- ₹3.00 Cr
MosChip Technologies Fund Raise of ₹112.2 Cr
MosChip Technologies approved a preferential issue of 50,50,686 equity shares at Rs.222 to 69 investors, raising about Rs.112.19 Crore. The board approval covers the fund raise, with an AGM/postal ballot dated 25 November 2026.
- Value
- ₹112.2 Cr
Cholamandalam Investment & Finance Company Fund Raise
Cholamandalam's board approved a Qualified Institutions Placement fund raise on 28 October 2026, subject to shareholder postal ballot. The quantum, price and terms remain undetermined.
Bodhi Tree Multimedia Fund Raise
Bodhi Tree Multimedia's EOGM on October 28, 2026, sought approval for a qualified institutions placement. The filing states no issue size.
Avalon Technologies Fund Raise of ₹425 Cr
Avalon Technologies' board approved a preferential warrant issue to Zollner Elektronik AG worth about ₹425 Crore. Shareholder approval is required at an EGM on 21 November 2026.
- Value
- ₹425.0 Cr
- Execution
- Warrants exercisable within 18 months from allotment
Sealmatic India Fund Raise of ₹15.01 Cr
Sealmatic India's board approved a ₹15.01 Crore preferential issue of 3,61,620 equity shares at ₹415 to two non-promoter investors. Shareholder approval at EGM is pending.
- Value
- ₹15.01 Cr